{"id":"W4366603286","doi":"10.1080/10428194.2023.2196593","title":"Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy","year":2023,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Genentech; Servier; Astellas Pharma; Galecto; Sierra Oncology; CTI Biopharma; Incyte; Pfizer; CareDx; MorphoSys; Celgene; Bristol-Myers Squibb; AstraZeneca; Constellation Pharmaceuticals; Italfarmaco; Menarini Group; Astellas Pharma US; Gilead Sciences; U.S. Department of Defense","keywords":"Ruxolitinib; Myelofibrosis; Medicine; Myeloproliferative neoplasm; Clinical trial; Janus kinase; Expanded access; Internal medicine; Oncology; Bone marrow; Cytokine","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001140477,0.0006569248,0.001613987,0.002495913,0.0002214772,0.001040524,0.0007975058,0.0008231555,0.003242886],"category_scores_gemma":[0.002216715,0.0002959103,0.00109752,0.002699865,0.000326574,0.001246104,0.0005344679,0.001365315,0.0009017723],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007412046,"about_ca_system_score_gemma":0.001359519,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001090278,"about_ca_topic_score_gemma":0.002626152,"domain_scores_codex":[0.9996411,0.0000752651,0.00009410767,0.00005979954,0.0001070456,0.00002274272],"domain_scores_gemma":[0.999022,0.000549685,0.0001469376,0.00001910427,0.0002182218,0.00004400505],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"systematic_review","study_design_scores_codex":[0.0002152127,0.000037648,0.0002518966,0.04617127,0.0003566214,0.0002060983,0.00008413757,0.0003012775,0.0007877561,0.001886729,0.02907782,0.9206235],"study_design_scores_gemma":[0.00007612807,0.0002840787,0.002097404,0.03215004,0.001156936,0.001735035,0.0001211193,0.0001510299,0.0004327664,0.001262555,0.9604952,0.00003759717],"study_design_candidate":"systematic_review","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001316367,0.9990946,0.00003533678,0.0002321301,0.000123416,0.000003612313,0.00002455356,0.000003109462,0.0003516128],"genre_scores_gemma":[0.0008739728,0.9982621,0.00009599486,0.0003922024,0.000109947,0.000005748042,0.00004350105,0.000001694826,0.0002148847],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.003242886,"threshold_uncertainty_score":0.01084852,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07429801613504322,"score_gpt":0.3947768205150981,"score_spread":0.3204788043800549,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}